Related Experiment Videos
Macromolecular infarct-specific magnetic resonance contrast agents
1Department of Radiology, University of Massachusetts Medical Center, Worcester.
Investigative Radiology
|June 1, 1994
Summary
Researchers developed novel phosphonate-based magnetic resonance imaging (MRI) agents. These agents effectively target myocardial infarction (MI) in preclinical models, showing promise for improved diagnostic imaging.
Area of Science:
- Biomedical Imaging
- Cardiovascular Research
- Materials Science
Background:
- Magnetic resonance imaging (MRI) is crucial for diagnosing myocardial infarction (MI).
- Developing targeted MRI contrast agents enhances diagnostic accuracy and specificity.
- Infarct-avid agents can improve the visualization of damaged heart tissue.
Purpose of the Study:
- To investigate phosphonylated macromolecules as targeted MRI agents for infarction.
- To assess the safety and efficacy of these novel phosphonate-based agents.
- To evaluate their potential for low-dose, infarct-specific imaging.
Main Methods:
- Synthesis of phosphonylated radiolabeled macroaggregates (gadolinium-153, iron-59).
- Biodistribution studies in rat models of myocardial infarction.
- Evaluation in rabbit models of myocardial infarction with occlusion and reperfusion.
- Assessment of MRI contrast properties (relaxivities) and imaging performance.
Main Results:
- Phosphonylated agents demonstrated preferential accumulation in infarcted heart tissue.
- Significant differences in agent concentration between infarct and normal tissue (70 +/- 30 nmol Fe/g vs. 9 +/- 2 nmolFe/g).
- Clear visualization of infarct zones using MRI with low-dose agents, correlating with histology.
Conclusions:
- Simple phosphonylated macromolecules serve as effective, low-dose MRI agents for infarction.
- These agents exhibit infarct-specific targeting capabilities.
- Potential for improved diagnostic imaging of myocardial infarction.